Navigation

Skiplink Navigation

Main Features

Roche to pay SFr20 million to Chiron

The Swiss pharmaceutical group, Roche, has been ordered to pay $20 million (SFr33 million) to the United States biotechnology group, Chiron.

The decision follows a ruling by the European Patent Office that Roche infringed Chiron's licence for sales related to its "HIV patent 150", which is used in clinical diagnostic and blood screening products

The fine covers sales prior to October 2000, after which Roche and Chiron had signed a broad patent licence deal for nucleic acid probe-based clinical diagnostics for HIV-1.

The German companies Bayer and Organon Teknika will also be paying compensation to Chiron for infringing its licence.

The US group's patent expires in 2005.

swissinfo with agencies


Links

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletter and get the top stories delivered to your inbox.

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

×